We are live on ! Find out more

Gossamer Bio

GOSS

Market cap $65.6M

10.70 USD

-0.03

0.28%

At close Updated Sep 14, 4:00 PM EDT

Pre-market

After hours

10.70

0.00

0%

1 day

-0.28%

5 days

-22.01%

1 month

-13.29%

3 months

-19.91%

6 months

-70.67%

Year to date

-95.36%

1 year

-95.79%

5 years

-98.7%

10 years

-99.25%

About: Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).

Employees: 162

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 15.4%

Neutral 76.9%

Negative 7.7%

Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, today announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to eff.

Gossamer Bio Announces Effectiveness of 1-for-80 Reverse Stock Split

Gossamer Bio Announces 1-for-80 Reverse Stock Split

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, today announced that its board of directors (the “Board”) has selected a 1-for-80 reverse stock split of the Company's common stock and a proportionate reduction in the number.

Gossamer Bio Announces 1-for-80 Reverse Stock Split

Gossamer Bio to Present at Cantor Global Healthcare Conference

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will present at the Cantor Global Healthcare Conference to take place on September 9-11, 2026. Cantor Global Healthcare Conference Date / Time: September 9th,.

Gossamer Bio to Present at Cantor Global Healthcare Conference

Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that it has entered into a securities purchase agreement with certain new and existing institutional investors for a private placement financing.

Gossamer Bio Announces Up to $250 Million Structured Private Placement, Including $150 Million of Committed Capital, to Fund Seralutinib Through Potential FDA Approval

Zacks Investment Research

Gossamer Bio (GOSS) Reports Q2 Loss, Tops Revenue Estimates

Gossamer Bio (GOSS) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.17 per share a year ago.

Gossamer Bio (GOSS) Reports Q2 Loss, Tops Revenue Estimates

Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update

SAN DIEGO--(BUSINESS WIRE)---- $GOSS--Gossamer Bio, Inc. (Nasdaq: GOSS) (the “Company” or “Gossamer”), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the second quarter ended June 30, 2026, and provided a business update. “We have worked hard to strengthen Gossamer and.

Gossamer Bio Announces Second Quarter 2026 Financial Results and Provides Business Update

Kuehn Law Encourages Investors of Gossamer Bio, Inc. to Contact Law Firm

NEW YORK, Aug. 10, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Gossamer Bio, Inc. (NASDAQ: GOSS) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Gossamer Bio misrepresented or failed to disclose material information regarding its Phase 3 PROSERA study evaluating seralutinib for the treatment of pulmonary arterial hypertension (PAH).

Kuehn Law Encourages Investors of Gossamer Bio, Inc. to Contact Law Firm

This Honeywell Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

This Honeywell Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Tuesday

Gossamer Bio Restructures Debt, Secures Full Control of Lead Drug Candidate

Gossamer Bio Inc. (NASDAQ:GOSS) stock is trading higher on Monday as the company is preparing to submit a New Drug Application (NDA) for its lead candidate, seralutinib, in September 2026 following a pre-NDA Type B meeting with the U.S. Food and Drug Administration (FDA).

Gossamer Bio Restructures Debt, Secures Full Control of Lead Drug Candidate

Gossamer Bio, Inc. (GOSS) Discusses Reacquisition of Seralutinib Rights, Regulatory Progress and Capital Structure Updates Transcript

Gossamer Bio, Inc. (GOSS) Discusses Reacquisition of Seralutinib Rights, Regulatory Progress and Capital Structure Updates Transcript

Gossamer Bio, Inc. (GOSS) Discusses Reacquisition of Seralutinib Rights, Regulatory Progress and Capital Structure Updates Transcript

See News Rankings

Price charts implemented using Lightweight Charts™